Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease
Science Translational Medicine · 03.04.2024 · 16 (741)
DOI: 10.1126/scitranslmed.adj0133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 03.04.2024. Verfasst von Ziyan Pan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW 2145, Australia. Hauptthemen laut MEDLINE: Liver, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Transforming growth factor–β (TGFβ) drives fibrosis and disease progression in a number of chronic disorders, but targeting this ubiquitously expressed cytokine may not yield a viable and safe antifibrotic therapy. Here, we sought to identify alternative ways to inhibit TGFβ signaling using human hepatic stellate cells and macrophages from humans and mice in vitro, as well as mouse models of liver, kidney, and lung fibrosis. We identified Mer tyrosine kinase (MERTK) as a TGFβ-inducible effector of fibrosis that was up-regulated during fibrosis in multiple organs in three mouse models. We confirmed these findings in liver biopsy samples from patients with metabolic dysfunction-associated fatty liver disease (MAFLD). MERTK also induced TGFβ expression and drove TGFβ signaling resulting in a positive feedback loop that promoted fibrosis in cultured cells. MERTK regulated both canonical and noncanonical TGFβ signaling in both mouse and human cells in vitro. MERTK increased transcription of genes regulating fibrosis by modulating chromatin accessibility and RNA polymerase II activity. In each of the three mouse models, disrupting the fibrosis-promoting signaling loop by reducing MERTK expression reduced organ fibrosis. Pharmacological inhibition of MERTK reduced fibrosis in these mouse models either when initiated immediately after injury or when initiated after fibrosis was established. Together, these data suggest that MERTK plays a role in modulating organ fibrosis and may be a potential target for treating fibrotic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW 2145, Australia.
- Westmead Research Hub, Westmead Institute for Medical Research, Sydney, NSW 2145, Australia.
- Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW 2010, Australia.
- St. Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
- Centre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW 2145, Australia.
- Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.
ORCID-Profile: Ziyan Pan, Rasha El Sharkway, Ali Bayoumi, Mayada Metwally, Brian S Gloss, Robert Brink, David Bo Lu, Christopher Liddle, Saleh A Alqahtani, Jun Yu, Philip J O'Connell, Jacob George, Mohammed Eslam
Zitieren
APA
Pan, Z., El Sharkway, R., Bayoumi, A., Metwally, M., Gloss, B. S., Brink, R., Lu, D. B., Liddle, C., Alqahtani, S. A., Yu, J., O'Connell, P. J., George, J., & Eslam, M. (2024). Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Science Translational Medicine, 16(741). https://doi.org/10.1126/scitranslmed.adj0133
Vancouver
Pan Z, El Sharkway R, Bayoumi A, Metwally M, Gloss BS, Brink R, et al. Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Science Translational Medicine. 2024;16(741). doi:10.1126/scitranslmed.adj0133
BibTeX
@article{Pan2024,
author = {Pan, Ziyan and El Sharkway, Rasha and Bayoumi, Ali and Metwally, Mayada and Gloss, Brian S and Brink, Robert and Lu, David Bo and Liddle, Christopher and Alqahtani, Saleh A and Yu, Jun and O'Connell, Philip J and George, Jacob and Eslam, Mohammed},
title = {Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {741},
doi = {10.1126/scitranslmed.adj0133}
}
EUVIMED